The Impact of COVID-19 on Access to Parkinson's Disease Medication

Julia Ling Yu Cheong, Zhao Hang Keith Goh, Connie Marras, Caroline M. Tanner, Meike Kasten, Alastair J. Noyce*

*Korrespondierende/r Autor/-in für diese Arbeit


BACKGROUND: Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income. METHODS: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. RESULTS: Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all ‘yes' respondents reported increased disability of patients as an impact. CONCLUSIONS: Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries.

ZeitschriftMovement Disorders
Seiten (von - bis)2129-2133
PublikationsstatusVeröffentlicht - 28.08.2020

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)


  • Forschung zu SARS-CoV-2 / COVID-19


Untersuchen Sie die Forschungsthemen von „The Impact of COVID-19 on Access to Parkinson's Disease Medication“. Zusammen bilden sie einen einzigartigen Fingerprint.